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Background: RASopathies are a group of disorders related to Noonan syndrome that with dysregulated
RAS-mitogen-activated protein kinase (MAPK) signaling pathway. Noonan syndrome (NS, OMIM# 163950) is
a both phenotypically and genotypically variable disorder. We and other researchers have demonstrated
that copy number variations underlie a small percentage of patients with RASopathies.
Results: In a cohort of 12 clinically characterized patients with congenital heart defect (CHD) and features
suggestive of Noonan syndrome or Noonan like syndrome without known causative gene mutation, we
performed an Illumina SNP-array analysis to identify the pathogenic copy number variations (Human660W-Quad
Chip, Beadstation Scanner and GenomeStudio V2011 software).
We identifed two rare copy number variations harboring genes involved in RAS- MAPK signaling pathway of
RASopathy. One is a 24 Mb duplication of 12q24.1-24.3 containing PTPN11 and the other is a 183 kb deletion
of 10q25.2 including SHOC2. The SNP-array results were further validated by quantitative PCR (qPCR). This is
might be the first report suggesting that haploinsufficiency of SHOC2 can result in a RASopathy-like phenotype.
Conclusions: Our findings provide additional support that copy number variations containing disease-causing
genes of RAS/MAPK pathway play a minor role in RASopathies or related disorders. We recommend the use
of microarrays in Noonan syndrome like patients without identified mutations in the causative genes.
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variation, CNV, Congenital heart defectBackground
RASopathies define a group of disorders clinically re-
lated to Noonan syndrome, which are caused by germ-
line mutations in genes encoding components in the
RAS-mitogen-activated protein kinase (MAPK) signaling
pathway [1-3]. Over the past decade, several genes
including PTPN11 (50% of patients with NS), SOS1
(5-10%), RAF1 (5-10%), KRAS (2%), BRAF (2%), NRAS,
MEK1, SHOC2, CBL and RIT1 have been identified in
70-75% of affected cases [4-9]. Recent studies using* Correspondence: tanzhiping@gmail.com
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unless otherwise stated.high-resolution chromosomal microarrays (SNP-array or
CGH-array) suggest that copy number variations in-
volved aforementioned genes. Duplications of 12q24
encompassing PTPN11 have been identified as an un-
common cause of NS [10-12]. In 2012, we reported the
first case suggestive of Noonan syndrome carrying a
microduplication of RAF1 [13]. In 2013, haploinsuffi-
ciency of MAP2K2/MEK2 was proposed as a novel
mechanism for the pathogenesis of RASopathies [14].
In this study, we described two additional patients
with distinct phenotype. A 183 kb deletion of 10q25.2
including SHOC2 and a 24 Mb duplication of 12q24.1-
24.3 containing PTPN11 were identified in a sporadic
case. Our results add new insights that copy number
variations play an import role in the etiology of NS
patients without known causative gene mutations.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This study was approved by the Review Board of the
Second Xiangya Hospital of the Central South University
for research involving human subjects. Written consent
to publish photographs of all the patients as well as clin-
ical data were obtained from the parents of the patients.
Patients
Patient 1
Patient 1 was first seen in our Department of Cardio-
thoracic Surgery at the age of 14 years because of heart
defect, ventricular septal defect (VSD). Further clinical
evaluation revealed distinctive facial features includingFigure 1 Craniofacial features of patient 1(A-D). (A) one year old, (B) an
slanting palpebral fissures, a large mouth with downturned corners, a short
duplications in previously report showing the relative positions of PTPN11 a
duplications. The smallest overlap region (108.2 Mb-113.6 Mb) is indicateddownward slanting palpebral fissures, a large mouth with
downturned corners, a short webbing neck and low pos-
terior hairline (Figure 1). Other abnormalities included
widely spaced nipples, thoracic scoliosis to right and
clinobrachydactyly. The proband is the only child of
healthy non-consanguineous parent with normal family
history. The patient was born at term of gestation after
an uncomplicated pregnancy and delivery. She was born
with a weight of 3,200 g (50th centile) and a height of
49 cm (50th centile). Pectus excavatum became more
obvious since six years old. She had developmental
delay, crawling at age of two and walking at three years
old. She had a speech delay and can only speak singled (C) 14 years old, Note the distinctive facial features, downward
webbing neck and low posterior hairline. (D) Schematic of the
nd TBX5. The upper seven black bars represent the reported
in blue bar. Genomic data have been converted to Hg19.
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weight of 35 kg (3rd centile), and a length of 120 cm
(3rd centile). She had severe mental retardation which
needs special education.
Patient 2
Patient 2 was an 11-year-old girl who had complex CHD
and entered our Department of Cardiothoracic Surgery
for surgical correction. She was the first child of aFigure 2 Clinical features of patient 2(A-E). Lateral (A, C) and frontal (B)
a large nasal tip and a long midface with a large mouth and crowding tee
removed preaxial polydactyly. (F) Human 660w-Quad SNP-array analysis of
shows a 0.18 Mb deletion in 10q25.2 (chr10: 112611576-112795021/Hg19).
deleted genes are showed in the lower panel.healthy non-consanguineous parent. She was born at full
term with a weight of 3,150 g (50th centile) and a height
of 50 cm (50th centile). She had severe cyanotic heart
disease (double outlet right ventricle, DORV and a large
20 mm VSD). Preaxial ploydactyly was observed in the
right hand (Figure 2) and was surgically removed at the
age of two years. Clinical evaluation revealed dysmorphic
features, including facial asymmetry, microcephaly with
sparse eyebrow, a large nasal tip, a long midface with aview of the patient. The patient has facial asymmetry, sparse eyebrow,
th. (D) Hands and (E) feet of the patient. Arrow indicates the surgically
the 10q25.2 deletion including SHOC2 in the Patient 2. SNP-array
Log R ratio and B allele frequency are showed in the upper panel;
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was performed at the age of 12 years. She weighed 30 kg
(10th centile) with a height of 150 cm (50th centile).
Neurological assessment showed normal intelligence, how-
ever with some behavioral disorders such as hyperactivity.
DNA extraction
The parents of the patient gave written informed con-
sent and genomic DNA was prepared from peripheral
blood of the patient and his parents. Genomic DNA was
prepared using a DNeasy Blood & Tissue Kit (Qiagen,
Valencia, CA) on the QIAcube automated DNA extrac-
tion robot (Qiagen, Hiden, Germany).
Mutation sequencing
The entire coding regions, including the flanking intronic
sequences of aforementioned 10 genes associated with NS
or Noonan like syndrome, were amplified with polymerase
chain reaction (PCR; primer sequences will be provided
upon requests). Sequences of the PCR products were
determined using the ABI 3100 Genetic Analyzer (ABI,
Foster City, CA) as previously described [15,16].
SNP array analysis
The Human660W-Quad Chip (Illumina Inc, San Diego,
USA) and the Illumina BeadScan genotyping system
(Beadstation Scanner) were employed to obtain the sig-
nal intensities of probes (SNP) following the manufac-
turer’s instructions. The GenomeStudio V2011 software
was used to analyze the genotypes (human genome build
37/Hg19) and evaluate the experimental quality. The call
rates of the samples are greater than 99.0%.
Quantitative PCR validation
To validate variable copy numbers, real-time quantita-
tive PCR (qPCR) were performed using the 7500 Fast
Real-Time PCR systems (Applied Biosystems, Foster
City, California). Two primer sets were designed within
the boundaries of the CNV region. Primer pairs were
designed by an online tool (PrimerQuest, IDT) (http://
www.idtdna.com/Primerquest/Home/Index). PCR reac-
tions were prepared with the SYBR Premix Ex Taq II
PCR reagent kit (TaKaRa Bio, Dalian, China) according
to the manufacturer’s protocol. Amplification efficiencies
were identical and the relative copy number was calcu-
lated with the 2-ΔΔCt method.
Results
We report here two additional patients with distinct
phenotypes suggesting RASopathies. Both patients have
a characteristic facial feature, congenital heart defects,
skeletal malformations and ectodermal abnormalities
(e.g. sparse hair and sparse eyebrow). Bidirectional se-
quencing of the aforementioned causative genes did notidentify any pathogenic mutations. We hypothesized that
chromosome structural variations might underlie both
cases and employed SNP-array to identify such possible
changes (Illumina Human660W-Quad) [17]. To identify
the de novo possible pathogenic CNVs, we examined gen-
omic DNA samples from parent-patient trios and identi-
fied a 24 Mb duplication of 12q24.1-24.3 containing
PTPN11 in Patient 1 (chr12:108235593-132289191/Hg19)
(Figure 1, Additional file 1: Figure S1), and a 183 kb
deletion of 10q25.2 including SHOC2 in Patient 2 (chr10:
112611576-112795021/Hg19) (Figure 2). Parents of both
patients did not carry the related genomic lesions.
Discussion
In this study, we report on two patients with molecularly
confirmed diagnosis of RASopathy carrying different
chromosomal imbalances, but all contained a critical
gene related to the RAS/MAPK signaling pathway.
Patient 1 (12q24.1-24.3 duplication) has some typical
features of NS, such as webbed neck, short stature, se-
vere developmental delay and pectus excavatum. A con-
genital heart defect (ventricular septal defect, VSD) was
identified by echocardiogram and was surgically repaired
in our Department of Cardiothoracic Surgery. To date,
Ten cases (including this study) have been reported to
carry similar 12q24 duplication encompassing PTPN11
[10-12,18]. In order to reveal possible candidate genes
involved in the pathogenesis of 12q24 duplication, we
aligned the chromosomal duplication region in reported
individuals. Our study of Patient 1 further narrowed the
critical region to a 5.4 Mb interval (108.2 Mb-113.6 Mb)
(Figure 1A). About 55 genes, including PTPN11 and
TBX5, are located in this duplication region. Given that
overexpression of TBX5 has been associated with cardiac
development, we could not exclude the possibility that the
cardiac defect (VSD) found in Patient 1 might be a conse-
quence of TBX5 duplication. Also some phenotypes that
might not be associated with RASopathies could be
explained by the contribution of the other critical genes
in the duplicated region, i.e. severe developmental
disability and ocular anomalies could be caused by
UBE3B [19], and brachydactyly could be explained by
TRVP4 [20].
Activating gain-of-function mutations in SHOC2 cause
NS with loose anagen hair. Interestingly, only one recur-
rent SHOC2 mutation (p.S2G) has been described [21].
A high frequency of short stature (100%) and intellectual
disability (84%) was observed in NS with loose anagen
hair [21]. However, Patient 2 (10q25.2 deletion) had nor-
mal stature and normal intelligence, though with unique
phenotype such as preaxial polydactyly of the right hand
(Figure 1B). We hypothesize that this novel 10q25.2
deletion might represent a previously unrecognized dis-
order. Beside SHOC2, BBIP1 (also known as NCRNA
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BBIP1 was recently shown to cause a recessive type of
Bardet-Biedl syndrome with retinitis pigmentosa, obesity,
kidney failure, cognitive disability and brachydactyly [22],
phenotypes that are obviously different from our patient.
We determined the sequences of the entire coding
and flanking intronic regions of BBIP1 and failed to
identify a mutation in the existing allele of BBIP1
(primer pairs are included in the Additional file 2:
Table S1). Therefore BBIP1 mutations might not underlie
this disorder.
CHD is observed in 50-75% of patients with syn-
dromes of the RAS-MAPK signaling pathway [23,24].
Pulmonary valve stenosis (PS) and atrial septum defect
(ASD) are frequently observed in patients with NS. The
most commonly cardiac defects in patients with SHOC2
mutation are dysplasia of the mitral valve and septal de-
fects [21]. In our study, patient 2 (deletion of SHOC2)
had DORV, which was seldom reported in Noonan syn-
drome or Noonan-like syndrome [25].
Despite extensive efforts to identify disease-causing
genes in NS and NS-like disorders, approximately
25-30% of patients remain genetically undiagnosed. It
highlights multiple pathogenic mechanisms underlying
RASopathy. The majority of the mutations identified in
the RASopathies are gain-of-function which resulted in in-
creased RAS/MAPK signaling. However, loss-of-function
mutations are also reported to cause LEOPARD syndrome
[26]. Previous studies have demonstrated that copy number
variations containing disease-causing genes play a minor
role in RASopathies [12,13]. Furthermore, happloinsuffi-
cency of MAP2K2/MEK2 was recently reported be a novel
mechanism for the etiology of RASopathies [14]. In line
with these findings, our study that deletion of SHOC2 pro-
vides additional evidence that microdeletion containing
one of the components of the RAS/MAPK pathway could
result in Noonan syndrome related disorder.
Conclusions
We describe pathogenic copy number variations in two
individuals, a 24 Mb duplication of 12q24 containing
PTPN11 resulted in apparent Noonan syndrome, while the
183 kb deletion of 10q25.2 including SHOC2 contributed
to atypical Noonan-like syndrome. To our knowledge, de-
letion of SHOC2 might be the first report in RASopathies.
Our study also provides additional support that copy num-
ber variations containing disease-causing genes of RAS/
MAPK pathway play a minor role in RASopathies.
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a 24 Mb duplication of 12q24 containing PTPN11 (chr12:108235593-
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BBIP1 in Patient 2.
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